The biologic therapy for asthma, ‘Cinqair,’ is actively expanding its prescription area in Korea.

According to industry sources, Teva-Handok’s monoclonal antibody Cinqair (reslizumab), which targets interleukin (IL)-5, has passed the drug committees (DC) of tertiary hospitals in Korea such as the Gangnam Severance Hospital, Samsung Medical Center, Seoul National University Hospital, and Seoul Asan Medical Center.

The drug has been landing in hospitals in Korea after being listed for reimbursement in October last year.

Cinqair has been granted reimbursement 8 years after failing its first attempt to enter the reimbursement system when it was approved in Korea in